Clinical Trials

FSD Pharma Inc. announced that the U.S. FDA has authorized the initiation of a Phase 2 study for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the “FSD201...

INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. FDA has notified the company it has additional questions about the company's...

Genetron and its partner CStone Pharmaceuticals have commenced a clinical trial in China, to jointly develop a companion diagnostic (CDx) test for avapritinib. Discovered by Blueprint Medicines, Avapritinib is a US Food and Drug Administration (FDA) approved kinase inhibitor, to...

Innovent Biologics, a biopharmaceutical company, announced the results of a phase 3, open label, randomized study in China. The ORIENT-32 trial evaluating Tyvyt (sintilimab injection) in combination with Byvasda (bevacizumab biosimilar injection, or IBI305) as a first-line treatment in...

FUJIFILM Toyama Chemical Co., Ltd. has announced that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” conducted in Japan for patients with novel coronavirus infections (hereinafter “COVID-19”). The efficacy primary endpoint is time to...

A groundbreaking interim report on a clinical trial being conducted in three hospitals has shown that Covid-19 patients on natural treatment are resolving most symptoms earlier than those on conventional medicines. The interim report on combination treatment of an Ayurvedic...

Veeva Systems and Bioforum announced their collaboration with RedHill Biopharma Ltd. on a global Phase 2/3 clinical study evaluating opaganib (Yeliva®, ABC294640),1 a first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, in patients hospitalized with severe COVID-19 pneumonia requiring treatment...